CHCHD10 variants in amyotrophic lateral sclerosis: Where is the evidence?. Issue 1 (31st August 2018)

• Record Type: Journal Article
• Other Names: Tazelaar Gijs H.P. investigator.; van Rheenen Wouter investigator.; Pulit Sara L. investigator.; van der Spek Rick A.A. investigator.; Dekker Annelot M. investigator.; Moisse Matthieu investigator.; McLaughlin Russell L. investigator.; Sproviero William investigator.; Kenna Kevin P. investigator.; Kooyman Maarten investigator.; van Doormaal Perry T.C. investigator.; van Eijk Kristel E. investigator.; Middelkoop Bas M. investigator.; Schellevis Raymond D. investigator.; Brands William J. investigator.; Al‐Chalabi Ammar investigator.; Morrison Karen E. investigator.; Shaw Pamela J. investigator.; Shaw Christopher E. investigator.; Newhouse Stephen E. investigator.; van Es Michael A. investigator.; Basak A. Nazli investigator.; Akçimen Fulya investigator.; Kocoglu Cemile investigator.; Tunca Ceren investigator.; Povedano Monica investigator.; Mora Jesus S. investigator.; Glass Jonathan D. investigator.; Van Damme Philip investigator.; Robberecht Wim investigator.; HardimanMD Orla investigator.; Landers John E. investigator.; van den Berg Leonard H. investigator.; Veldink Jan H. investigator.;
• Is Part Of: Annals of neurology. Volume 84:Issue 1(2018)
• Page Start: 110
• Page End: 116
• Publication Date: 2018-08-31
• Subjects: Neurology -- Periodicals; Pediatric neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; 616.8
• DOI: 10.1002/ana.25273
• Languages: English
• ISSNs: 0364-5134

Abstract

Abstract : Objective: After the initial report of a CHCHD10 mutation in mitochondrial disease with features resembling amyotrophic lateral sclerosis (ALS), CHCHD10 mutations have been considered to be a frequent cause for ALS. However, the exact pathogenicity and clinical significance of these mutations remain unclear. Here, we aimed to determine the role of CHCHD10 mutations in ALS. Methods: We analyzed 4, 365 whole genome sequenced ALS patients and 1, 832 controls from 7 different countries and examined all nonsynonymous single nucleotide variants in CHCHD10. These were tested for association with ALS, independently and in aggregate using several genetic burden tests (including sequence kernel association test [SKAT], optimal unified test [SKAT‐O], and Firth logistic regression). Results: We identified 3 new variants in cases, but only 1 was ALS‐specific. Also, 1 control‐specific mutation was identified. There was no increased burden of rare coding mutations among ALS patients compared to controls ( p = 0.86, p = 0.86, and p = 0.88 for SKAT, SKAT‐O, and Firth, respectively). The few carriers with potential pathogenic CHCHD10 mutations exhibited a slowly progressive ALS‐like phenotype with atypical features such as myopathy and deafness. Interpretation: CHCHD10 mutations seem to be a far less prevalent cause of pure ALS than previously suggested, and instead appear related to more complex phenotypes. There appears to be insufficient evidence for the pathogenicity of most previously reported variants in pure ALS. This study shows that routine testing for CHCHD10 mutations in pure ALS is not recommended and illustrates the importance of sufficient genetic and functional evidence in establishing pathogenicity of genetic variants. Ann Neurol 2018;83:110–116